Company Updates-SHENZHEN Hemogen Therapeutic Co.,Ltd，简称: HGI.

2026 03-04

Breakthrough: Hemogen’s SPARK Model Successfully Validated in Thailand, Expanding Global Solutions for Thalassemia Gene Therapy

In Southeast Asia, where thalassemia remains highly prevalent, patients continue to face limited access to advanced gene therapy and insufficient loca...

2026 02-27

Hemogen’s Hemo-cel Demonstrates Durable Clinical Benefit in β-Thalassemia, Supporting Global Partnership and Commercialization Potential

Hemogen announced the publication of clinical results for its lead gene therapy candidate, hemo-cel (HGI-001 injection), in the peer-reviewed journal ...

2026 02-06

From Innovation to Impact: Hemogen Highlights the Future of Hematopoietic Stem Cell Gene Therapy

Leveraging years of research and translational experience in hematopoietic stem cell gene therapy (HSC-GT), Hemogen was invited to author the rev...

2025 11-25

Hemogen Therapeutics Presents at SEATPA Inaugural Meeting and Highlights SPARK Global Deployment Solution

Chiang Mai, Thailand — November 24, 2025Hemogen Therapeutics was invited to participate in the inaugural meeting of the Southeast Asia Thalassemia Pre...

2025 11-16

Hemogen Therapeutic Granted Special “White List” Status for Cross-Border Transport of Biomedical Materials — Enabling a New International Logistics Channel and Improving Global Patient Access to Gene Therapies

On November 14, 2025, the Joint Regulatory Mechanism Office for the Cross-Border Management of Special Biomedical Items in Shenzhen announced the prop...

2025 11-16

Hemogen Therapeutic Wins the “Outstanding Clinical Achievement in Cell Therapy” Award Driving Global Gene Therapy Adoption Through Indigenous Innovation and International Expansion

Shenzhen, China — November 2025Hemogen Therapeutic announced that it has been awarded the “Outstanding Clinical Achievement in Cell Therapy” at the 14...

2025 05-30

Revolutionizing CGT Cell Processing Technology, Celaxi - 23 Leads the New Industry Benchmark

In the field of cell and gene therapy (CGT), efficient and stable cell purification and elutriation are the core links to ensure efficacy and safety. ...

2025 04-15

Hemogen’s Hemocel (HGI-001 Injection) Receives ThaiFDA Clinical Trial Approval and Successfully Completes Manufacturing Equipment Transfer Validation

Shenzhen Hemogen Therapeutic Co., Ltd. (hereinafter referred to as “Hemogen”) has achieved a significant milestone in its international...

PA视讯shouji

SHENZHEN Hemogen Therapeutic Co., Ltd.

Company Updates

Breakthrough: Hemogen’s SPARK Model Successfully Validated in Thailand, Expanding Global Solutions for Thalassemia Gene Therapy

Hemogen’s Hemo-cel Demonstrates Durable Clinical Benefit in β-Thalassemia, Supporting Global Partnership and Commercialization Potential

From Innovation to Impact: Hemogen Highlights the Future of Hematopoietic Stem Cell Gene Therapy

Hemogen Therapeutics Presents at SEATPA Inaugural Meeting and Highlights SPARK Global Deployment Solution

Hemogen Therapeutic Granted Special “White List” Status for Cross-Border Transport of Biomedical Materials — Enabling a New International Logistics Channel and Improving Global Patient Access to Gene Therapies

Hemogen Therapeutic Wins the “Outstanding Clinical Achievement in Cell Therapy” Award Driving Global Gene Therapy Adoption Through Indigenous Innovation and International Expansion

Revolutionizing CGT Cell Processing Technology, Celaxi - 23 Leads the New Industry Benchmark

Hemogen’s Hemocel (HGI-001 Injection) Receives ThaiFDA Clinical Trial Approval and Successfully Completes Manufacturing Equipment Transfer Validation

PA视讯shouji

Company Updates

Breakthrough: Hemogen’s SPARK Model Successfully Validated in Thailand, Expanding Global Solutions for Thalassemia Gene Therapy

Hemogen’s Hemo-cel Demonstrates Durable Clinical Benefit in β-Thalassemia, Supporting Global Partnership and Commercialization Potential

From Innovation to Impact: Hemogen Highlights the Future of Hematopoietic Stem Cell Gene Therapy

Hemogen Therapeutics Presents at SEATPA Inaugural Meeting and Highlights SPARK Global Deployment Solution

Hemogen Therapeutic Granted Special “White List” Status for Cross-Border Transport of Biomedical Materials — Enabling a New International Logistics Channel and Improving Global Patient Access to Gene Therapies

Hemogen Therapeutic Wins the “Outstanding Clinical Achievement in Cell Therapy” Award Driving Global Gene Therapy Adoption Through Indigenous Innovation and International Expansion

Revolutionizing CGT Cell Processing Technology, Celaxi - 23 Leads the New Industry Benchmark

Hemogen’s Hemocel (HGI-001 Injection) Receives ThaiFDA Clinical Trial Approval and Successfully Completes Manufacturing Equipment Transfer Validation

Hemogen Therapeutic Granted Special “White List” Status for Cross-Border Transport of Biomedical Materials — Enabling a New International Logistics Channel and Improving Global Patient Access to Gene Therapies

Hemogen Therapeutic Wins the “Outstanding Clinical Achievement in Cell Therapy” Award Driving Global Gene Therapy Adoption Through Indigenous Innovation and International Expansion